These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 15381472)

  • 1. A doctor talks about. Screening for ovarian cancer.
    Robb-Nicholson C
    Harv Womens Health Watch; 2004 Sep; 12(1):5. PubMed ID: 15381472
    [No Abstract]   [Full Text] [Related]  

  • 2. Ovarian cancer screening. American College of Radiology. ACR Appropriateness Criteria.
    Böhm-Vélez M; Mendelson E; Bree R; Finberg H; Fishman EK; Hricak H; Laing F; Sartoris D; Thurmond A; Goldstein S
    Radiology; 2000 Jun; 215 Suppl():861-71. PubMed ID: 11037511
    [No Abstract]   [Full Text] [Related]  

  • 3. By the way, doctor. I received a widely circulated e-mail message about use of the CA-125 blood test in screening for ovarian cancer. The message suggested that the CA-125 test be used for routine screening, like a Pap smear. Do you agree? What's your opinion of this test?
    Robb-Nicholson C
    Harv Womens Health Watch; 2001 Jul; 8(11):8. PubMed ID: 11511469
    [No Abstract]   [Full Text] [Related]  

  • 4. My friend says I should get a CA 125 test to check for ovarian cancer. Should I have this test done?
    Mayo Clin Womens Healthsource; 2007 Sep; 11(9):8. PubMed ID: 17700510
    [No Abstract]   [Full Text] [Related]  

  • 5. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic markers for early detection of ovarian cancer.
    Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
    Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
    Ødegaard E; Davidson B; Elgaaen BV; Fagerhol MK; Engh V; Onsrud M; Staff AC
    Am J Obstet Gynecol; 2008 Apr; 198(4):418.e1-7. PubMed ID: 18241816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer screening and peritoneal carcinomatosis: standards, 'omics' and miRNAs for personalized management.
    Spiliotis J; Halkia E; Roukos DH
    Expert Rev Mol Diagn; 2011 Jun; 11(5):465-7. PubMed ID: 21707454
    [No Abstract]   [Full Text] [Related]  

  • 11. Biomarkers for the early detection of cancer: an inflammatory concept.
    Roy HK; Khandekar JD
    Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302
    [No Abstract]   [Full Text] [Related]  

  • 12. Are there new ways to test my blood for ovarian cancer?
    Health News; 2004 Nov; 10(11):16. PubMed ID: 15655869
    [No Abstract]   [Full Text] [Related]  

  • 13. Ovarian cancer screening.
    Eason EL
    CMAJ; 2005 Feb; 172(4):447. PubMed ID: 15710918
    [No Abstract]   [Full Text] [Related]  

  • 14. The quest for ovarian cancer's Holy Grail: can CA-125 still be the chalice of early detection?
    Karlan BY; McIntosh M
    J Clin Oncol; 2007 Apr; 25(11):1303-4. PubMed ID: 17416848
    [No Abstract]   [Full Text] [Related]  

  • 15. Pre-operative prediction of serum CA125 level in women with ovarian masses.
    Benjapibal M; Neungton C
    J Med Assoc Thai; 2007 Oct; 90(10):1986-91. PubMed ID: 18041413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The myth of measurable disease in ovarian cancer: revisited.
    Markman M
    Cancer Invest; 2009 Jan; 27(1):11-2. PubMed ID: 19160094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
    Camlica H; Duranyildiz D; Tas F; Yasasever V
    Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA-125 as a biomarker for malignant transformation of endometriosis.
    Check JH
    Fertil Steril; 2009 May; 91(5):e35; author reply e36. PubMed ID: 19338996
    [No Abstract]   [Full Text] [Related]  

  • 20. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
    ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
    Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.